Valeant Pharma (VRX) on Watch as Ahead of Pershing Square Conference Call

Valeant Pharmaceuticals (VRX) Bull-Bear Debate Rages

October 30, 2015 12:57 PM EDT

The bull-bear battle in beaten up and highly-questioned Valeant Pharma (NYSE: VRX) took center stage again today. Bill Ackman from Pershing Square on the bull side and Andrew Left from Citron Research on the bear side. Currently the bears are winning and the stock is down another 10% today and again below the $100 level.

This morning the company announced that it is severing all ties with Philidor Rx and Philidor has informed Valeant that it will shut down operations as soon as possible. Valeant's controversial... More

Bill Ackman said Valeant Pharma (VRX) worth $180-$240 Near-Term, $262-$350 Long-Term

October 30, 2015 10:14 AM EDT

On the Valeant Pharma (NYSE: VRX) call, Bill Ackman said Valeant worth $180-$240 and worth $262-$350 longer term (2020).

... More

Amazon (AMZN) Should Distribute Drugs - Ackman

October 30, 2015 9:26 AM EDT

On its Valeant Pharma (NYSE: VRX) call, Bill Ackman suggests Amazon.com (NASDAQ: AMZN) should distribute drugs. He said the specialty pharmacy model is future, cutting out wholesalers.

... More

Pershing Square Valeant Pharma (VRX) Conf. Call Up and Running after Technical Difficulties

October 30, 2015 9:14 AM EDT

After initially crashing on heavy volume, Bill Ackman's conference call on Valeant Pharma (NYSE: VRX) is up and running again after technical difficulties.

It can be found here: http://livestream.com/PershingSquare/events/4464622

... More

Valeant Pharma (VRX) Appoints Former U.S. Deputy AG Filip to Advise Ad Hoc Committee

October 30, 2015 8:46 AM EDT

Valeant Pharma (NYSE: VRX) announced that the ad hoc committee appointed by Valeant's board of directors has appointed former Deputy Attorney General of the United States Mark Filip of Kirkland & Ellis LLP to advise the committee in its review of allegations related to Valeant's... More

Evercore ISI's Raffat Provides Thoughts on Valeant Pharma (VRX)

October 30, 2015 8:14 AM EDT

Evercore ISI's Umer Raffat weighed in on Valeant Pharma (NYSE: VRX) following press reports last night on Philidor's drug dispensing practices and news this morning that Valeant is severing all ties to Philidor is a step in the right direction.

Raffat said he... More

Stocks slip but post best month in four years

October 30, 2015 7:32 AM EDT

By Lewis Krauskopf

(Reuters) - U.S. stock indexes finished with their strongest monthly performances in four years on Friday, even as they dipped for the day amid a mixed bag of earnings reports.

For October, all three major indexes posted their biggest percentage increases since October 2011, with the S&P 500 rising 8.3 percent, led by energy and materials, while a measure of volatility fell.

On Friday, CVS Health (NYSE: CVS) fell 4.8 percent to $98.78 after a disappointing profit forecast for 2016.

The S&P 500 energy index was the best performing sector, rising... More

BTIG Downgrades Valeant Pharmaceuticals (VRX) to Neutral

October 30, 2015 6:49 AM EDT

BTIG downgraded Valeant Pharmaceuticals (NYSE: VRX) from Buy to Neutral.

The firm noted: We believe Valeant needs to sever its relationship with the specialty pharmacy Philidor and move on. Until that occurs, we can no longer have a positive view on the... More

Valeant Pharma (VRX) to Sever Ties with Philidor

October 30, 2015 5:59 AM EDT

Valeant Pharma (NYSE: VRX) announced that it is severing all ties with Philidor Rx Services, LLC, and that Philidor has informed Valeant that it will shut down operations as soon as possible, consistent with applicable laws.

"The newest allegations about activities at Philidor raise additional questions about the company's business practices," said J. Michael Pearson, Valeant's... More